ADR Reporting: How Adverse Drug Reactions Are Monitored Globally

 

Introduction: When Medicines Cause Harm

No medicine is without risk. Even the most carefully developed and rigorously tested pharmaceutical product can cause unintended effects in some patients — effects that may not have been apparent during clinical trials conducted in controlled populations. Adverse Drug Reaction (ADR) reporting is the global mechanism through which these unintended effects are systematically identified, documented, and communicated to the regulatory authorities and healthcare professionals responsible for protecting patient safety.

For any professional working in drug safety or clinical research, understanding how ADR reporting works — across both clinical trial and post-marketing settings — is a foundational competency. Students enrolled in Pharmacovigilance Courses in Pune will recognise ADR reporting as one of the most practically important and frequently assessed skills in the entire PV curriculum.

What is an Adverse Drug Reaction? Definitions That Matter

The precise definition of an ADR matters enormously in a regulatory context, because it determines what must be reported, to whom, and within what timeframe. The WHO defines an ADR as a response to a medicine that is noxious and unintended, and that occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function.

This definition distinguishes ADRs from adverse events (AEs) — a broader term used in clinical trials to capture any untoward medical occurrence in a patient receiving a study drug, regardless of whether it is causally related to that drug. An adverse event becomes an adverse drug reaction when a causal relationship is considered at least a reasonable possibility. This distinction is critical for classification and reporting purposes.

Classification of Adverse Drug Reactions

ADRs are classified in multiple ways depending on the context. The most widely used classification system is the Rawlins-Thompson system, which categorises ADRs into six types:

•         Type A (Augmented): Dose-dependent, predictable reactions related to the pharmacological action of the drug — the most common type, accounting for approximately 80 percent of all ADRs

•         Type B (Bizarre): Idiosyncratic reactions unrelated to the drug's pharmacological action, often immunological in nature — less common but frequently more severe

•         Type C (Chronic): Effects associated with long-term drug use, such as adrenal suppression with corticosteroids

•         Type D (Delayed): Reactions that appear some time after drug exposure, including carcinogenicity and teratogenicity

•         Type E (End of use): Withdrawal reactions occurring when a drug is discontinued abruptly

•         Type F (Failure): Unexpected failure of therapy, often due to drug interactions or subtherapeutic dosing

The Global ADR Reporting System: How It Works

Spontaneous Reporting

Spontaneous reporting is the foundation of global pharmacovigilance. Healthcare professionals, patients, and pharmaceutical companies submit reports of suspected adverse drug reactions directly to national regulatory authorities or through designated reporting portals. In the US, this is done through the FDA's MedWatch system. In Europe, reports are submitted to EudraVigilance. Globally, national reports feed into the WHO's VigiBase — the world's largest database of individual case safety reports, containing over 30 million records.

The Role of National Pharmacovigilance Centres

Each WHO member country is encouraged to establish a national pharmacovigilance centre responsible for collecting, processing, and analysing ADR reports from within the country and contributing data to VigiBase. India's national centre is the Indian Pharmacopoeia Commission (IPC) in Ghaziabad, which coordinates the Pharmacovigilance Programme of India (PvPI) — a network of adverse drug reaction monitoring centres across hospitals and medical institutions nationwide. Students completing a Pharmacovigilance Course in Pune should develop a thorough understanding of PvPI's structure, the VigiFlow reporting system used by Indian ADR monitoring centres, and the role that CDSCO plays in overseeing national pharmacovigilance activities.

Expedited Reporting for Serious Adverse Events

Not all ADR reports are treated equally. Serious and unexpected adverse drug reactions — particularly those that are fatal, life-threatening, or result in hospitalisation — must be reported to regulatory authorities within accelerated timelines. For fatal or life-threatening unexpected serious adverse reactions, the reporting timeline is 7 days (with a follow-up report within 15 days). For other unexpected serious reactions, the timeline is 15 days. These timelines apply across most major regulatory jurisdictions, including CDSCO, the FDA, and the EMA — and failure to meet them is a significant compliance violation with serious regulatory consequences.

ADR Reporting in Clinical Trials

During clinical trials, ADR reporting follows a parallel but more structured process governed by GCP requirements and the specific study protocol. Any adverse event observed at a trial site must be documented in the Case Report Form and assessed by the investigator for seriousness, severity, and causality. Serious Adverse Events (SAEs) must be reported to the sponsor within 24 hours of the site becoming aware — and the sponsor is then responsible for evaluating whether the event meets the criteria for expedited reporting to regulatory authorities as a Suspected Unexpected Serious Adverse Reaction (SUSAR). Students completing a Clinical Research Course in Pune will cover this entire workflow — from site-level AE documentation through sponsor safety review to regulatory submission — as a core component of the clinical research curriculum.

MedDRA: The Language of ADR Reporting

Adverse drug reactions cannot be reported, compared, or analysed at a global level unless they are described using a standardised medical terminology. MedDRA — the Medical Dictionary for Regulatory Activities — is the internationally recognised terminology used to classify adverse events, medical history, indications, and other medical concepts in regulatory submissions and pharmacovigilance databases worldwide. Proficiency in MedDRA coding — understanding how to select appropriate preferred terms, system organ classes, and high-level terms — is a core technical skill for every drug safety professional and is assessed in virtually every PV job interview.

Conclusion: ADR Reporting is Where Patient Safety Becomes Real

Adverse drug reaction reporting is not a bureaucratic compliance activity — it is the mechanism through which real patients' safety experiences are translated into the global knowledge base that protects future patients. Every ICSR submitted, every signal generated from aggregate data, every label updated in response to emerging ADR patterns represents pharmacovigilance working as intended.

For students in Pune who are serious about building a career in drug safety, mastering ADR reporting is the most important practical skill you can develop. Well-structured Clinical Research Institute in Pune that incorporate pharmacovigilance modules — covering ICSR processing, MedDRA coding, and regulatory reporting timelines — ensure that you graduate with the exact skills that CROs and pharmaceutical safety teams are hiring for right now.